Kardes Hakan
Known title: Chief Experience OfficerCIK: 0001975023
Associated companies
Transaction History
| ALHC | ▼ Sell | Open Market | 7,225 | $129K | 3/27/2025 | View on chart |
| ALHC | ▼ Sell | Open Market | 4,229 | $68K | 3/19/2025 | View on chart |
| ALHC | ▼ Sell | Open Market | 2,373 | $40K | 3/19/2025 | View on chart |
| ALHC | ▼ Sell | Open Market | 25,000 | $425K | 3/18/2025 | View on chart |
| ALHC | ▲ Buy | Grant | 39,677 | $0 | 3/13/2025 | View on chart |
| ALHC | ▼ Sell | Open Market | 4,787 | $74K | 3/12/2025 | View on chart |
| ALHC | ▼ Sell | Open Market | 69 | $1K | 3/12/2025 | View on chart |
| ALHC | ▼ Sell | Open Market | 86,659 | $1.3M | 3/6/2025 | View on chart |
| ALHC | ▲ Buy | Grant | 474,208 | $0 | 3/4/2025 | View on chart |
| ALHC | ▼ Sell | Open Market | 14,500 | $217K | 1/24/2025 | View on chart |
| ALHC | ▼ Sell | Open Market | 10,500 | $157K | 1/21/2025 | View on chart |
| ALHC | ▼ Sell | Open Market | 35,000 | $448K | 11/27/2024 | View on chart |
| ALHC | ▼ Sell | Open Market | 20,500 | $268K | 11/4/2024 | View on chart |
| ALHC | ▼ Sell | Open Market | 4,500 | $58K | 11/1/2024 | View on chart |
| ALHC | ▼ Sell | Open Market | 25,000 | $287K | 9/12/2024 | View on chart |
| ALHC | ▼ Sell | Open Market | 25,000 | $250K | 7/16/2024 | View on chart |
| ALHC | ▼ Sell | Open Market | 4,363 | $21K | 3/28/2024 | View on chart |
| ALHC | ▼ Sell | Open Market | 18,964 | $96K | 3/19/2024 | View on chart |
| ALHC | ▼ Sell | Open Market | 4,326 | $21K | 3/15/2024 | View on chart |
| ALHC | ▲ Buy | Grant | 140,190 | $0 | 3/13/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
ALHC Faces Downgrade and Lower Target Amid Mixed CMS Ratings
Alignment Healthcare shares are trading lower after William Blair downgraded the stock to Market Perform and JP Morgan cut its price target to $10. These moves followed mixed California Star Ratings and news of network expansion, which analysts say highlight ongoing operational challenges. The stock is currently trading near its 52-week low, reflecting the negative sentiment from these recent analyst actions.
ALHC Faces Downgrade and Lower Target Amid Mixed CMS Ratings. Alignment Healthcare shares are trading lower after William Blair downgraded the stock to Market Perform and JP Morgan cut its price target to $10. These moves followed mixed California Star Ratings and news of network expansion, which analysts say highlight ongoing operational challenges. The stock is currently trading near its 52-week low, reflecting the negative sentiment from these recent analyst actions.